Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Provista Life Sciences
Provista Life Sciences PLS Announces Initiation of the BT Test Validation Study in the United Kingdom
December 2nd, 2008
Provista Life Sciences LLC (PLS) announced that the National Health System's Ethical Committee approval has been granted to proceed with a validation study of its Biomarker Translation Test (BT Test) in the United Kingdom (UK). The BT Test, a new blood test developed by Provista Life Sciences to aid healthcare providers in early breast cancer detection, will undergo a validation study in the UK to be conducted in conjunction with the Cambridge University Hospital's (Addenbrooke's) Breast Unit. The validation study is anticipated to begin recruitment in November 2008 and to have the study completed within the next 9 months. PLS is a medical diagnostics development and...
Source: Cancer Weekly (2008-12-02)
|
